- Home
- NEGG vs STRO Comparison
NEGG vs STRO Comparison
Compare NEGG & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | STRO |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 85.0M |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NEGG | STRO |
|---|---|---|
| Price | $52.43 | $11.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.29 |
| AVG Volume (30 Days) | ★ 132.1K | 125.6K |
| Earning Date | 12-01-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,313,127,000.00 | $105,646,000.00 |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $5.23 |
| 52 Week High | $137.84 | $21.50 |
Technical Indicators
Market Signals| Indicator | NEGG | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 82.73 |
| Support Level | $53.32 | $8.49 |
| Resistance Level | $59.21 | $11.09 |
| Average True Range (ATR) | 4.84 | 0.87 |
| MACD | -1.24 | 0.03 |
| Stochastic Oscillator | 2.38 | 83.01 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.